EACH CHEWABLE TABLET CONTAINS: FLURALANER…. 1000 MG
- TREATMENT AND PREVENTION OF TICK AND FLEA INFESTATIONS ON DOGS FOR 3 MONTHS.
- TREATMENT OF DEMODICOSIS CAUSED BY DEMODEX SPP. MITES, SARCOPTIC MANGE AND OTODECTES SPP. MITE INFESTATIONS IN DOGS
BRAVECTO kills fleas and prevents flea infestations for 12 weeks. BRAVECTO Chew and BRAVECTO Topical Solution for Dogs kills ticks (black-legged tick, American dog tick, and brown dog tick) for 12 weeks and also kills lone star ticks for 8 weeks. BRAVECTO Topical Solution for Cats kills black-legged ticks for 12 weeks and American dog ticks for 8 weeks.
IMPORTANT SAFETY INFORMATION
BRAVECTO has not been shown to be effective for 12-weeks’ duration in puppies or kittens less than 6 months of age. Fluralaner is a member of the isoxazoline class. This class has been associated with neurologic adverse reactions including tremors, ataxia, and seizures. BRAVECTO Chew for Dogs: The most commonly reported adverse reactions include vomiting, decreased appetite, diarrhea, lethargy, polydipsia, and flatulence. BRAVECTO is not effective against lone star ticks beyond 8 weeks of dosing. Seizures have been reported in dogs receiving isoxoline class drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. BRAVECTO Topical Solution for Dogs: The most commonly reported adverse reactions include vomiting, hair loss, diarrhea, lethargy, decreased appetite, and moist dermatitis/rash. Bravecto is not effective against lone star ticks beyond 8 weeks of dosing. For topical use only. Avoid oral ingestion. Seizures have been reported in dogs receiving isoxoline class drugs, even in dogs without a history of seizures. Use caution in dogs with a history of seizures or neurologic disorders. BRAVECTO Topical Solution for Cats: The most commonly reported adverse reactions include vomiting, itching, diarrhea, hair loss, decreased appetite, lethargy, and scabs/ulcerated lesions. BRAVECTO is not effective against American dog ticks beyond 8 weeks of dosing. For topical use only. Avoid oral ingestion. The safety of BRAVECTO has not been established in breeding, pregnant and lactating cats. Neurologic adverse reactions have been reported in cats receiving isoxazoline class drugs, even in cats without a history of neurologic disorders. Use with caution in cats with a history of neurologic disorders.
References:
1. BRAVECTO Chew for Dogs [prescribing information]. Madison, NJ: Merck Animal Health; 2014. 2. BRAVECTO Topical Solution for Dogs [prescribing information]. Madison, NJ: Merck Animal Health; 2016. 3. BRAVECTO Topical Solution for Cats [prescribing information]. Madison, NJ: Merck Animal Health; 2016. 4. Freedom of Information Summary, NADA 141-426. Approved May 15, 2014. 5. Freedom of Information Summary, NADA 141-459. Approved July 20, 2016. 6. Lavan et al. J Vet Sci Technol. 2017;8:439. 7. Dryden et al. Parasites & Vectors. 2015;8:364. 8. Dryden et al. Parasites & Vectors. 2018;11:422. 9. Burgio et al. Parasites & Vectors. 2016;9:626. 10. CAPC website, Guidelines–Ticks. Available at www.capcvet.org/guidelines/ticks/. Updated April 2017. Accessed December 20, 2018. 11. Walther et al. Parasites & Vectors. 2014;7:86. 12. Walther et al. Parasites & Vectors. 2014;7:481.
